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ABSTRACT
Purpose To measure aggregate and particle formation in tu-
mor necrosis factor-alpha (TNF-α) inhibitors etanercept,
adalimumab and certolizumab pegol product samples after
exposure to freezing temperature conditions similar to storage
conditions previously observed in patients’ homes.
Methods TNF-α inhibitors in their original primary and sec-
ondary packaging were exposed to 32 freeze-thaw cycles
(−10°C for 120min/5°C for 60 min) or continuous low stor-
age temperature (−20°C for 96 h) before thawing at 2–8°C.
Non-stressed products were used as controls. The products
were analyzed by high pressure size exclusion chromatogra-
phy (HP-SEC), dynamic light scattering (DLS), nanoparticle
tracking analysis (NTA), micro-flow imaging (MFI) and sec-
ond derivative ultraviolet (UV) spectroscopy.
Results Ten out of twenty-one stressed product samples
(47.6%) showed increased particle numbers in the submicron
and micron size range when compared to controls. For each
product, DLS, MFI and NTA detected an increase in particle
level in at least one stressed syringe (both continuous freezing
and freeze-thaw), whereas HP-SEC and UV spectroscopy
showed no differences between stressed and non-stressed
products.
Conclusion TNF-α inhibitors are relatively resistant to freez-
ing temperatures similar to storage conditions previously ob-
served in patients’ homes. However, almost half of the stressed
product samples showed formation of particles in the submi-
cron and micron size range.
KEY WORDS aggregation of antibodies . drug product
characterization . freezing stress conditions . home storage .
TNF-α inhibitors
ABBREVIATIONS
DLS Dynamic light scattering
ECD Equivalent circular diameter
HP-SEC High pressure size exclusion chromatography
MALLS Multi angle laser light scattering
MFI Micro-Flow Imaging
NTA Nanoparticle tracking analysis
PdI Polydispersity index
TNF-α Tumor necrosis factor-alpha
UV Ultraviolet light
INTRODUCTION
The introduction of drugs containing tumor necrosis factor-
alpha (TNF-α) inhibitors has revolutionized treatments for
many inflammatory diseases such as rheumatoid arthritis
and inflammatory bowel disease [1]. TNF-α inhibitors, and
other biologic drugs, differ from the traditional small molecule
drugs as these are large complex proteins which are more
prone to physical instability processes when exposed to
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external stress factors such as heat, freeze-thawing and agita-
tion [2]. Due to the specific characteristics of biological drugs,
these products need to comply with specific stability test pro-
grams and should be assessed regarding their potential immu-
nogenicity [3,4]. According to the Summary of Product
Characteristics documentation of TNF-α inhibitors, it is ad-
vised to store these products between 2°C and 8°C, not to
expose them to freezing or agitation, and to protect them from
light exposure [5,6].
A previous study showed that most patients do not
store TNF-α inhibitors within this recommended tem-
perature range; only 7% of patients were able to store
TNF-α inhibitors continuously between 2 and 8°C [7].
Almost 25% of patients stored their TNF-α inhibitors
below 0°C for 2 h or longer; 5.9% of patients stored
their TNF-α inhibitors below 0°C for at least 24 h, with
the lowest temperature measured around −20°C. In ad-
dition, almost 14% of the patients exposed their TNF-α
inhibitors to at least three re-current freeze-thaw cycles
with a median duration of almost 4 days. Six patients
(2.4%) even exposed their drugs to at least 32 recurrent
freeze-thaw cycles [7]. The most common consequence
of exposing proteins to freezing temperature conditions
is the formation of aggregates [8,9] which may lead to
the development of antidrug antibodies and decreased
drug effectiveness, as well as an increased probability
of side effects [10,11].
Experimental data have shown that extreme low tempera-
tures (−80°C) and multiple freeze-thaw cycles can induce for-
mation of antibody aggregates in different non-commercial
protein formulations [12,13]. However, it is unclear if
marketed TNF-α inhibitors in their original formulation and
primary container will undergo similar structural changes
when exposed to less extreme low temperatures or multiple
freeze-thaw cycles as observed in consumer refrigerators. The
aim of this study was to assess aggregate and particle forma-
tion in TNF-α inhibitor product samples when exposed to




The following TNF-α inhibitors were kept in the original
primary and secondary packaging and exposed to differ-
ent temperature conditions as observed in the study by
Vlieland et al. [7]: adalimumab 40 mg/0.8ml (six product
samples Humira® A1-A5), certolizumab pegol 200 mg/ml
(six product samples Cimzia® C1-C5), originator/
biosimilar etanercept 50 mg/ml products (seven product
samples Enbrel®(originator) E1-E6; six product samples
Benepali® (biosimilar) B1-B5 (Table I). One package of
adalimumab and certolizumab pegol contained two prod-
uct syringes, packages of etanercept (originator and
biosimilar) contained four product syringes. The tested
TNF-α inhibitors have dif ferent characteris t ics :
adalimumab is a human-derived recombinant monoclonal
antibody, etanercept is a fusion protein (two TNF-α re-
ceptors and a human Fc fragment), certolizumab pegol is
a pegylated anti-TNF-α antibody Fab’ fragment. We
injected all (stressed and control) drug products from the
prefilled syringe via the needle through the Teflon lined,
pre-slitted screw caps into 1.5 mL sample vials, thereby
mimicking as closely as possible a true injection by a pa-
tient. Prior to characterization, product samples were pre-
pared with the following corresponding formulation
buffers: etanercept: 10mg/ml sucrose, 5.8mg/ml NaCl,
5.3 mg/ml arginine, 3.9 mg/ml Na2HPO4.H2O,
pH 6.3; adalimumab: 1.3 mg/ml citric acid, 1.5 mg/ml
Na2HPO4.2H2O, 0.86 mg/ml NaH2PO4.2H2O,
12 mg/ml mannitol, 1 mg/ml polysorbate 80, 6.2 mg/ml
NaCl, 0.3 mg/ml sodium citrate, pH 5.2; certolizumab:
0.28mg/ml (10mM) sodium acetate, 7.3 mg/ml (125 mM)
NaCl, pH 4.7.
Applied Freezing Stress Conditions
Temperature conditions were simulated by usage of a Slow
Programmable Freezer (Sylab Icecube 1810). This freezer
makes use of liquid nitrogen and allows for applying storage
temperatures between +5°C and −20°C in a reliable setting
with little temperature variation (±0.5°C). TNF-α inhibitors
were exposed to temperature conditions based on the lowest
continuous temperature and recurrent freeze-thaw cycles ob-
served in patients’ homes (Fig. 1) and subsequently tested for
aggregate and particle formation. In the first stress protocol,
three samples from each product (A1-A3; C1-C3; E1-E3; B1-
B3) were exposed to multiple freeze-thaw cycles. Products
were held at −10°C for 120min and subsequently thawed
for 60 min at 5°C. This procedure was performed 32 times
for a total exposure time of 96 h. Freezing/thawing speed for
both stressing protocols was set to 1°C per minute. In the
second stress protocol, samples from each product (A4-A5;
C4-C5; B4-B5; E4-E6) were exposed to a continuous low
storage temperature (−20°C) for a period of 96 h before
thawing at refrigerator temperature (5°C). One sample from
each product (stored in a refrigerator between 2 and 8°C) was
used as control. All product samples were stored between 2
and 8°C before analysis.
Product Characterization
The formation of aggregates and particles, and changes
in protein conformation was determined by analyzing
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each stressed and non-stressed product with the methods
described below.
Dynamic Light Scattering (DLS)
With DLS aggregates in the size range from about 1 nm
to 1 μm can be detected. DLS was performed on a
Malvern Zetas izer Nano (Malvern, Herrenberg
Germany). 500 μl of the stressed and non-stressed product
samples were analyzed in plastic cuvettes at 25°C using
the automatic mode for identifying the best number of
subruns and measurement time (n = 3). The Z-average
diameter and polydispersity index (PdI) were calculated
from the correlation function using the Dispersion
Techno l ogy So f twa r e v e r s i on 7 . 03 (Ma l ve rn ,
Herrenberg, Germany). All product samples were mea-
sured undiluted, except for the certolizumab products,
which were diluted 4 fold with 0.28mg/ml (10mM) sodi-
um acetate, 7.3 mg/ml (125 mM) NaCl, pH 4.7 due to
the high viscosity of the product.
High Pressure Size Exclusion Chromatography (HP-SEC)
WithHP-SEC the amount of monomers, dimers and fragments
in the products can be detected and quantified. The non-
stressed and stressed product samples were analyzed by HP-
SEC, us ing a Yarra 3u SEC-2000 300 × 7.8mm
(Phenomenex, Torrance, CA, USA) on an Agilent 1200 chro-
matography system (Agilent Technologies, Palo Alto,
California) combined with a Wyatt Eclipse detector system
(Wyatt Technology Europe GmbH, Dernbach, Germany),
multi-angle laser light scattering (MALLS) detection with the
DAWN® HELEOSTM (Wyatt Technology Europe GmbH)
and at a flow rate of 0.5 ml/min. 5 μl of each diluted product
sample was injected. All product samples were diluted with
formulation buffer to a protein concentration of 1 mg/ml.
The mobile phase was composed of 50 mM phosphate,
150 mM arginine and 0.025% NaN3 at pH 6.5. To quantify
aggregation, UV absorption at 280 nmwas recorded. From the
MALLS signal, the root mean square (rms) diameter was cal-
culated using the Berry Fit in the Astra software version 5.3.2.22
(Wyatt Technology Europe GmbH, Dernbach, Germany).
Table I Product Sample Summary
Product Strength Volume Lot nr. Expiry date Buffer Control
samples
Stressed samples
Etanercept 2–8°C Freeze-thaw Continuous freezing




10 mg/ml sucrose, 5.8 mg/ml
NaCl, 5.3 mg/ml arginine,
3.9 mg/ml Na2HPO4.H2O, pH 6.3
1 3 (E1/E2/E3) 3 (E4/E5/E6)
Benepali® 50 mg 1.0 ml CT0037
CT0026
9/2018 1 3 (B1/B2/B3) 2 (B4/B5)
Adalimumab
Humira® 40 mg 0.8 ml 61145XD18 12/2017 1.3 mg/ml citric acid, 1.5 mg/ml
Na2HPO4.2H2O, 0.86 mg/ml
NaH2PO4.2H2O, 12 mg/ml
mannitol, 1 mg/ml polysorbate 80,
6.2 mg/ml NaCl, 0.3 mg/ml sodium
citrate, pH 5.2
1 3 (A1/A2/A3) 2 (A4/A5)
Certolizumab Pegol
Cimzia® 200 mg 1.0 ml 195,843 9/2017 0.28 mg/ml (10 mM) sodium acetate,
7.3 mg/ml (125 mM) NaCl, pH 4.7
1 3 (C1/C2/C3) 2 (C4/C5)
Fig. 1 Overview experiments showing four different products, storage conditions and different analyses. h = hours.
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Nanoparticle Tracking Analysis (NTA)
Particles between 20 and 1000 nm can be detected with NTA.
Measurements were performed with a NanoSight LM20,
equipped with a sample chamber with a 640-nm laser oper-
ating at an angle of 173° with respect to the flow cell. All
products were diluted with formulation buffer (Table I) to a
protein concentration of 5 mg/ml. The product samples were
injected into the chamber by an automatic pump (Harvard
Apparatus, catalog no. 98–4362, Holliston, USA) using a ster-
ile 1-ml syringe (BD Discardit II, Franklin Lakes, New Jersey).
For each product a 90 s video was captured with the shutter
set at 1495 and the gain at 400. Videos were analyzed by using
the NTA 2.0 Build 127 software. The following settings were
used for tracking of the particles: background extract on;
brightness 0; gain 1.00; blur size 3 × 3; detection threshold
10, viscosity equal to that of water. All other parameters were
set to the automatic adjustment mode.
Flow Imaging Microscopy
Micron sized particles up to 25 μm can be detected byMFI. A
Micro-Flow Imaging (MFI) system (MFI5200, ProteinSimple,
Santa Clara, USA), equipped with a silane coated flow cell
(1.41 × 1.76 × 0.1 mm) and controlled by the MFI View
System Software version 2, was used for flow imaging micros-
copy analysis. The systemwas flushed with 4 ml purified water
at 6 ml/min prior to each measurement. The flow cell clean-
liness was checked visually between measurements. The back-
ground was zeroed by flowing formulation buffer (Table I)
and performing the ‘optimize illumination’ procedure.
0.3 ml of each product sample (undiluted, only certolizumab
pegol was diluted fourfold due to high viscosity) without a pre-
run volume because of the limited amount of product was
analyzed at a flow rate of 0.17 ml/min and a fixed camera
shot rate of 22 flashes per second. The data recorded by the
system software was analyzed with MFI View Analysis Suite
version 1.2. For each product, stuck, edge, and slow moving
particles were removed by the software before data analysis.
Because no pre-run volume could be used, the data was re-
corded from the start of the measurement until the product
reached the flow cell. Therefore, data was processed in the
time window from 0.7 to 1.7 min, in which the measurement
was stable for all products. The equivalent circular diameter
(ECD), which is the diameter of a circle that has an area equal
to that of the particle imaged by MFI, was calculated and
presented as a measure of the particle size (1–100 μm).
Numbers of silicone oil droplet-like particles were calculated
for each product (only for particles ≥5 um) by visual identifi-
cation of typical oil droplets, which are round, have a smooth
surface and are black with a small whitish spot in the center. In
addition, we used the “find similar” procedure in the analysis
software to identify particles that have image characteristics
similar to those of the selected oil droplet-like particles [14].
Second Derivative UV Spectroscopy
Second derivative UV spectroscopy was used to detect confor-
mational changes in the products upon stress. Measurements
were performed using an Agilent 8453 UV–Vis spectrometer
(Agilent Technologies, Waldbronn, Germany) according to
the method described earlier (15). The product samples (dilut-
ed to 1 mg/ml) were measured in 2 ml half-micro quartz
cuvettes (Hellma Benelux, Kruibeke, Belgium) with a path
length of 10mm. The absorbance was measured from 240 to
340 nm with intervals of 1 nm using an integration time of
15 s. Background correction was performed with formulation
buffer, diluted accordingly in freshly filtered Milli-Q grade
water. The second derivatives of the spectra were calculated
with UV–Visible ChemStation Software (Agilent
Technologies, Walbronn, Germany) using a filter length of
9 nm and a polynomial degree of 4. Thereafter, the second
derivatives were splined using 99 data points between the 1-
nm measurement points. The vertical distance between the
minimum at 283 nm and the maximum at 287 nm is denoted
as ‘a’ and the vertical distance between the minimum and
maximum at 290 and 295 nm as ‘b’ [15]. The ratio a/b is
used to determine the exposure of tyrosine residues to bulk
solvent, which is sensitive to changes in the tertiary structure.
RESULTS
Temperature Stress Testing
All products were successfully exposed to the stress protocols
mimicking multiple freeze-thaw cycles and continuous freez-
ing temperatures.
Product Characterization
Dynamic Light Scattering (DLS)
The Z-average diameter and PdI results for non-stressed and
stressed products are summarized in Table II. Two product
samples showed an increase in Z-average and PdI (product sam-
ple E3: Z-average 17.48 (SD 0.01)/PdI 0.27 (SD 0.01); product
sample B3: Z-average 24.00 (SD 0.03)/PdI 0.27 (SD 0.03)) after
multiple freeze-thaw stress conditions. In one certolizumab
pegol product sample a difference in Z-average and PdI was
detected after continuous freezing compared to the non-
stressed product (C4: Z-average 10.13 (SD 0.02)/PdI 0.25 (SD
0.02)). Additional peaks in size distribution were detected after
both stress conditions; product samples E2, E3, B3 exposed to
multiple freeze-thaw stress conditions and product samples E4,
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C4, C5 exposed to continuous freezing stress conditions show
peaks between 4000 nm and 6000 nm.
High Pressure Size Exclusion Chromatography (HP-SEC)
For the non-stressed drug products, monomer content was
97.7% for etanercept (originator), 97.9% for etanercept
(biosimilar), 99.5% for adalimumab and 99.6% for
certolizumab pegol (Table II). After both stress test condi-
tions (multiple freeze-thawing and continuous freezing),
monomer and dimer content for all drug products did
not decrease compared to the non-stressed products
(Fig. 2). Corresponding molecular weights, based on
MALLS data, are presented in Table II for the main peak
Table II Second-Derivative UV Spectroscopy, DLS,NTA andHP-SEC Results for Etanercept (Originator and Biosimilar), Adalimumab and Certolizumab Pegol
Drug Products Under Non-Stress Conditions (2–8 °C), Freeze-Thawing and Continuous Freezing Stress Conditions
Etanercept (originator)
Non-stressed 2–8 °C Stressed (E1|E2|E3)
96 h FT− 10 °C/5 °C
Stressed (E4|E5|E6) 96 h− 20°C
DLS Z-average in nm (SD) 14.80 (0.01) 15.11 (0.00) 15.54 (0.01) 17.48 (0.01) 15.26 (0.01) 14.56 (0.00) 15.61 (0.02)
PdI (SD) 0.11 (0.01) 0.09 (0.00) 0.14 (0.01) 0.27 (0.01) 0.01 (0.01) 0.00 (0.00) 0.02 (0.02)
HP-SEC Monomer (%) 97.7 97.6 97.5 97.6 97.5 97.4 97.3
Dimer (%) 2.3 2.4 2.5 2.4 2.5 2.6 2.7
Molecular weight
(Da) Monomer
1.3*105 1.3*105 1.3*105 1.3*105 1.3*105 1.3*105 1.3*105
NTA (size estimation) Mean in nm (SD) 259 (120) 181 (116) 203 (104) 246 (118) 335 (127) 339 (121) 363 (125)
UV spectroscopy a/b ratio 0.96 0.96 0.96 0.96 0.97 0.93 0.96
Etanercept (biosimilar)
Non-stressed 2–8 °C Stressed (B1|B2|B3)
96 h FT− 10 °C/5 °C
Stressed (B4|B5) 96 h− 20 °C
DLS Z-average in nm (SD) 14.82 (0.01) 15.05 (0.01) 14.80 (0.01) 24.00 (0.03) 14.80 (0.01) 14.91 (0.01)
PdI (SD) 0.06 (0.01) 0.09 (0.01) 0.05 (0.01) 0.27 (0.03) 0.08 (0.01) 0.07 (0.01)
HP-SEC Monomer (%) 97.9 97.9 97.9 97.4 97.9 98.0
Dimer (%) 2.1 2.1 2.1 2.6 2.1 2.0
Molecular weight
(Da) Monomer
1.3*105 1.3*105 1.3*105 1.3*105 1.3*105 1.3*105
NTA (size estimation) Mean in nm (SD) 294 (151) 487 (99) 164 (86) 252 (119) 663 (345) 573 (261)
UV spectroscopy a/b ratio 0.96 0.95 0.96 0.96 0.96 0.97
Adalimumab
Non-stressed 2–8 °C Stressed (A1|A2|A2) 96 h FT− 10 °C/
5 °C
Stressed (A4|A5) 96 h− 20 °C
DLS Z-average in nm (SD) 16.28 (0.01) 16.07 (0.01) 15.25 (0.01) 15.82 (0.01) 15.48 (0.01) 15.51 (0.01)
PdI (SD) 0.03 (0.01) 0.04 (0.01) 0.02 (0.01) 0.03 (0.01) 0.03 (0.01) 0.03 (0.01)
HP-SEC Monomer (%) 99.5 99.7 99.8 99.8 99.8 99.8
Dimer (%) 0.5 0.3 0.2 0.2 0.2 0.2
Molecular weight
(Da) Monomer
1.6*105 1.4*105 1.4*105 1.4*105 1.5*105 1.5*105
NTA (size estimation) Mean in nm (SD) 328 (172) 252 (129) 205 (62) 281 (151) 246 (97) 325 (151)
UV spectroscopy a/b ratio 1.48 1.48 1.47 1.48 1.48 1.47
Certolizumab pegol
Non-stressed 2–8 °C Stressed (C1|C2|C3)
96 h FT− 10 °C/5 °C
Stressed (C4|C5) 96 h− 20 °C
DLS Z-average in nm (SD) 8.72 (0.01) 8.68 (0.02) 8.81 (0.00) 8.39 (0.01) 10.13 (0.02) 8.70 (0.01)
PdI (SD) 0.10 (0.02) 0.10 (0.02) 0.11 (0.00) 0.08 (0.01) 0.25 (0.02) 0.21 (0.01)
HP-SEC Monomer (%) 99.6 99.6 99.6 99.6 99.6 99.6
Dimer (%) 0.4 0.4 0.4 0.4 0.4 0.4
Molecular weight
(Da) Monomer
5.7*104 5.0*104 5.0*104 5.0*104 5.8*104 5.8*104
NTA (size estimation) Mean in nm (SD) 527 (176) 304 (122) 398 (137) 335 (162) 415 (177) 455 (240)
UV spectroscopy a/b ratio 2.64 2.65 2.65 2.65 2.63 2.65
Pharm Res (2018) 35: 42 Page 5 of 11 42
and correspond well with the expected molecular weights for
the respective monomeric proteins.
Nanoparticle Tracking Analysis (NTA)
For non-stressed products the following particle concentra-
tions were detected: etanercept (originator) 1.7*108 parti-
cles/ml, etanercept (biosimilar) 0.6*108 particles/ml,
adalimumab 0.3*108 particles/ml, certolizumab pegol
0.1*108 particles/ml. Two etanercept product samples
showed an increase in particle concentration after multiple
freeze-thaw cycles (product sample E3: 7.69*108 particles/
ml; product sample B1: 9.68*108 particles/ml), which was
not observed for the other products exposed to the same stress
conditions or continuous freezing. No differences in particle
concentrations were measured between non-stressed and
stressed (both multiple freeze-thawing and continuous freez-
ing) products of adalimumab and certolizumab pegol (Fig. 3).
Changes in particle size were detected in etanercept
(originator) and etanercept (biosimilar). Mean particle sizes
for non-stressed product samples were 259 nm (SD 120) and
294 nm (151), respectively (Table II). Stressed samples showed
larger mean particle sizes; E4: 335 nm (SD 127), E5: 339 (SD
121), E6: 363 (SD 125), B1: 487 nm (SD 99), B4: 663 nm (SD
345) and B5: 573 nm (SD 261).
Micro Flow Imaging (MFI)
The concentrations of particles ≥2, ≥5, ≥10 and ≥25 μm are
shown in Fig. 4. Representative images of particles are pre-
sented in Fig. 5. Non-stressed product sample for etanercept
(originator) contained 26,308 particles ≥2 μm/ml and non-
stressed product samples etanercept (biosimilar), adalimumab
and certolizumab pegol contained respectively 18,168, 5193
and 17,640 particles/ml sized 2 μm or larger. Differences in
particle concentrations were observed in etanercept products
exposed to multiple freeze-thaw stress conditions: etanercept
originator (product sample E3) and etanercept biosimilar
Fig. 2 HP-SEC chromatograms. UV detection was performed at 280 nm. Graphs show controls versus two freezing stressed product samples. Black lines
represent non-stressed product samples, red lines represent product samples exposed to freeze-thawing and orange lines represent product samples exposed to
continue freezing stress conditions.
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(product sample B3). Certolizumab pegol products showed an
increased particle concentration (C1, C2) after freeze-thaw
stress conditions. Continuous freezing stress conditions also
led to an increase in numbers of particles sized ≥2 μm in the
following product samples: etanercept E4, E5, E6, B4,
adalimumab product sample A5, certolizumab pegol product
samples C4, C5.
Besides analyzing the total particle numbers, we used the
“find similar” procedure of the MFI software to elucidate
whether the increased particle numbers were due to silicone
oil droplets, which could be released from the surface of the
primary packaging materials, or to proteinaceous particles, or
both. This distinction can be made for particles ≥5 μm based
onmorphological differences between silicone oil droplets and
protein aggregates [14]. The results indicated that product
samples (E4, E5, E6, B3, B4, A5) contained increased num-
bers of both silicone oil droplets and other, most likely pro-
teinaceous particles. The percentage of silicone oil droplet-like
particles in these product samples varied between 46% and
69% (for particles ≥5 μm; results not shown).
UV Spectroscopy
The a/b ratios for non-stressed etanercept (originator),
etanercept (biosimilar), adalimumab and certolizumab pegol
products were 0.96, 0.96, 1.48 and 2.64, respectively (Table I).
No changes in a/b ratios between stressed (multiple freeze-
thawing and continuous freezing) and non-stressed product
samples were detected. Moreover, the peak positions for
non-stressed product samples compared to stressed product
samples (both multiple freeze-thawing and continuous freez-
ing) were similar (results not shown).
Results Summary
A summary of the results of all analytical methods used to
detect and characterize aggregates and particles formed in
the different stressed products is shown in Table III. In at least
one sample of the four different products tested, to some ex-
tent more particles were detected compared to the non-
stressed sample. Particles in the submicron and micron size
range were detected in ten of the twenty-one TNF-α inhibitor
product samples (47.6%), six product samples upon exposure
to multiple freeze-thawing and four product samples after
exposure to continuous freezing conditions. With HP-SEC
and UV spectroscopy no differences in aggregate formation
were detected between stressed (both multiple freeze-thawing
and continuous freezing) and non-stressed products. With
DLS, differences in aggregate level between one product sam-
ple exposed to multiple freeze-thawing and the non-stressed
product sample were detected in etanercept originator and
biosimilar products. After continuous freezing stress condi-
tions, two etanercept (originator and biosimilar) product sam-
ples and certolizumab pegol product sample showed a higher
Z-average compared to the non-stressed product. NTA test-
ing showed differences in particle concentration in two
stressed etanercept product samples (one originator/one
biosimilar) upon freeze-thaw stress conditions compared to
the non-stressed products. This result corresponds partially
with DLS, for etanercept (originator) product sample E3,
where both methods detect increased aggregate levels.
Larger particles (>1 μm) were also detected with MFI:
etanercept (originator and biosimilar) and certolizumab pegol
showed an increased number of particles after freeze-thaw
stress conditions. After continuous freezing stress conditions,
in at least one product of etanercept (originator/biosimilar),
adalimumab and certolizumab pegol an increase in the num-
ber of large particles was detected.
DISCUSSION
This study shows that temperature conditions similar to those
that occur in patients’ homes have minor impact on the level
of aggregates and particles in product samples of etanercept
(Enbrel® and Benepali®), adalimumab (Humira®) and
certolizumab pegol (Cimzia®). Nevertheless, products ex-
posed to these temperature conditions contained more parti-
cles in the submicron andmicron size range. Almost half of the
product samples which were exposed to multiple freezing
stress conditions (47.6%; six freeze-thawing and four continu-
ous freezing) showed larger numbers of subvisible particles
(>1 μm) compared to non-stressed products.
Fig. 3 Nanoparticle tracking analysis (NTA). Black bars represent particle
concentrations in non-stressed products (C= control sample). Red bars rep-
resent particle concentrations in products exposed to freeze-thaw stress con-
ditions, Orange bars represent particle concentrations in products that were
exposed to continuous freeze conditions.
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Our results are qualitatively in line with other studies in-
vestigating the formation of aggregates in IgG antibody for-
mulations after exposure to freezing stress conditions, which
describe the formation of few aggregates >1 μm [13,16].
Although others have observed changes in monomer/di-
mer/oligomer content with HP-SEC and conformational
changes with UV spectroscopy [12,17], we did not find such
changes after exposing TNF-α inhibitors to freezing stress
conditions. Moreover, not all product samples showed elevat-
ed particle levels. For those product samples that did show
elevated particle levels by NTA and/or MFI, HP-SEC results
indicate that these particles corresponded to a minute fraction
of the total amount of protein. This low level of protein ag-
gregation may be due to the fact that in the current study we
used marketed products in their original formulation and pri-
mary container, whereas the cited studies were done on non-
commercial IgG molecules. Moreover, the stress conditions
applied in our study were relatively mild when compared to
the other studies. With DLS, three product samples (E3, B3,
C4) showed an increase in aggregate level after freezing stress
conditions. These results were partially in line with the NTA
data, showing the formation of particles in one etanercept
sample (E3) after multiple freeze-thawing, but not for
etanercept (biosimilar) samples and certolizumab pegol. MFI
data showed the formation of large aggregates (>1 μm) in at
least one sample of all products after both stress conditions
(E3, E4, B3, B4, A5, C1, C2, C4, C5), except for adalimumab
upon multiple freeze-thawing. In addition, an increase in the
number of silicone oil droplets was detected with MFI in some
product samples (E4, E5, E6, B3, B4, A5) with the percentages
of silicone oil droplets ranging between 46 and 69% [14].
Freeze-thawing has been described as having a smaller im-
pact on the stability of biologics compared to heating or agi-
tation and shows the formation of only few aggregates in the
micron and submicron size range [12]. Our observations con-
firm other findings suggesting that the level of aggregation
upon freeze-thaw stress is generally low with particles in the
low micron-size range as main degradation product
[12,17–19]. In this study products were exposed to two stress
conditions: multiple freeze-thawing and continuous freezing.
Fig. 4 MFI results. Grey and black bars represent particle counts in buffer (b) and control products (c), respectively. Red bars represent particle counts products
exposed to freeze-thaw stress conditions, orange bars represent particle counts in products that were exposed to continuous freeze conditions. Silicone oil
droplet counts in different products are represented for particles ≥5 μm by light grey bars in the opposite direction.
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Although one would expect that multiple freeze-thawing cy-
cles would have more impact than continuous freezing stress,
we did not observe such an effect. Subjecting products to
continuous low temperatures might increase ice crystal forma-
tion or ice texture changes in some of the products, thereby
increasing aggregation [20].
In theory, exposing products to inadequate storage condi-
tions as previously reported could induce the formation of
aggregates which could lead to the development of antidrug
antibodies and might subsequently affect treatment outcome
[10]. Although recent studies have shown that home storage
conditions for TNF-α inhibitors are often not adequate [7],
Fig. 5 MFI results. Examples of MFI images for all products tested, stressed and non-stressed. Particle size ranges are shown in equivalent circular diameter
(ECD). (−) = no particles in size range detected.
Table III Overview of Product Characterization Experiments, Freezing Stress Conditions and Product Samples in Which Aggregates Were Detected

















DLS Size range: <1 μm + 0 + 0 0 0 0 +
HP-SEC Relative amount
mono−/dimer/fragments
0 0 0 0 0 0 0 0
NTA Size range: <1 μm + 0 + 0 0 0 0 0
MFI Size range: >2 μm + + + + 0 + + ++
UV spectro-scopy Structural changes 0 0 0 0 0 0 0 0
FT Products exposed to freeze-thaw stress (96 h)
CF Products exposed to continue freeze stress (96 h)
0 no differences in aggregate/particle level in stressed vs unstressed products
+ higher aggregate/particle levels in at least 1 stressed vs unstressed product
++ higher aggregate levels in stressed vs unstressed products
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there is no evidence that this has resulted in the development
of antidrug antibodies or has had other clinical consequences
for patients. The relation between inadequate storage, protein
aggregation and immunogenicity has not been investigated in
humans due to ethical reasons, but a number of experiments
in animal models have shown that the amount, size, and na-
ture of aggregates to a certain extent determines the immuno-
genic potential of a protein drug [10,19]. A recent post mar-
keting study on peginesatide (an erythropoiesis-stimulating
agent) in relation to the occurrence of severe adverse events
(49 cases of anaphylaxis, including 7 fatalities) linked these
events to a higher concentration of subvisible particles [21].
A prospective study would be needed to investigate the com-
plex relation between storage conditions of TNF-α inhibitors,
aggregate formation, immunogenicity and therapy outcomes.
In this study, there were limitations concerning the number
of different TNF-α inhibitor products and the number of sam-
ples from each product that could be tested. The availability of
more samples and products for testing might have enabled us
to get a better andmore reliable assessment of aggregation risk
for different biological drugs that are not stored according to
label instructions. We only stressed products for 96 h, whereas
patients store products in their refrigerator for up to three
months. This difference might have resulted in an underesti-
mation of the number of products that contained aggregates
after freezing stress conditions. Extending the stress period
would give a better estimation how TNF-α inhibitor products
can change during home storage. In addition, we did not
assess other important stress conditions that TNF-α inhibitors
may be exposed to during transport and long storage periods,
such as agitation and light exposure. Exposure to conditions
outside the recommended storage conditions might also affect
container closure integrity of the drug product, which can
have impact on its stability and sterility. As this is one of the
first studies in its kind, more research is required in order to
investigate the consequences of inadequate storage for prod-
uct quality and its effect on immunogenicity and clinical re-
sponse on treatment with TNF-α inhibitors.
CONCLUSION
The studied TNF-α inhibitors remain relatively stable
with regard to the number of aggregates and particles
when exposed to temperature storage conditions seen at
patients’ homes. However, aggregation as a result of
freezing stress conditions appears to be probabilistic, as
we detected subvisible particles (>1 μm) in almost half
of the product samples. Low temperatures (−20°C) and
multiple freeze-thaw cycles as observed in consumer re-
frigerators can induce the formation of few aggregates in
different TNF-α inhibitor products.
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